Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) with potential antitumor activity for the study of the anti-PD-1 inhibitor budigalimab in non-small cell lung cancer.
Purity:
95.00%
CAS Number:
[2098225-93-3]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted